Soluble Co-Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case-Control Study.

23 A trial of abatacept, a CTLA‐4‐Ig used for the treatment of RA, in patients with GCA showed a slightly significant increase in relapse‐free survival at 12 months compared with controls. 42 Although the overall results of this trial were positive, the small effect of abatacept may suggest that this pathway is not a pivotal target in GCA, and indeed, an industry‐sponsored trial on the use of subcutaneous abatacept in patients with GCA ( NCT03192969 ) has been withdrawn.

also in 1,762 other papers